Senior Principal Scientist, Group Director

Pascal Chanu

Oncology, Immunology, and Ophthalmology

“My main motivation is to impact drug development using model-based approaches.”

Your role at Institut Roche and brief presentation of your professional background:

I joined Institut Roche in 2016 to support gRED (Genentech Research and Early Development) Clinical Pharmacology department. I am currently Group Director in the M&S group overseeing mainly projects in Oncology and Fibrotic disease.
I am Pharmacometrician and Clinical Pharmacologist with more than 20 years’ experience in M&S and drug development in hospitals (3 years), in the Pharma industry (11+ years, mainly in the Roche group) and consultancy (7+ years).

My Focus at Institut Roche:

I am providing M&S scientific oversight for half of the gRED Oncology portfolio and in fibrotic disease.

I am currently developing disease models for Multiple Myeloma and Geographic Atrophy and providing oversight in disease modeling in both oncology and non-oncology areas.

Cross-functional activities: I am also overseeing an initiative for the use of Real World Data (RWD) in Clinical Pharmacology. I am chairing the pediatric extrapolation cross-functional team.

  1. Julian C., Machado R.J.M., Girish S., Chanu P., Heinzmann D., Harbron C., Gershon A., Pfeiffer S.M., Zou W., Quarmby V., Zhang Q., Chen Y. Real-world data prognostic model of overall survival in patientswith advanced NSCLC receiving anti-PD-1/PD-L1 immunecheckpoint inhibitors as second-line monotherapy. Cancer Reports, 2022;e1578. doi:10.1002/cnr2.1578
  2. Chanu P., Musib L., Wang X., Cheeti S., Girish S., Bruno R., Lu T., Reddy J., Jin J.Y., Caro I. Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation. Journal of Investigative Dermatology, 141, 930-933, 2021.
  3. Felip E., Burotto M., Zvirbule Z., Herraez-Baranda L.A., Chanu P., Kshirsagar S., Maiya V., Chan P., Pozzi E. Marchand M., Monchalin M., Tanaka K., Tosti N., Wang B., Restuccia E. Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer. Clinical Pharmacology in Drug Development, 10, 1142-1155, 2021.
  4. Yoshida K., Wilkins J., Winkler J., Wade J.R., Kotani N., Wang N., Sane R., Chanu P. Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. Journal of Clinical Pharmacology, 61, 1579-1591, 2021.
  5. Chanu P., Schaefer F., Warady B.A., Schmitt C.PC, Reigner B., Schnetzler G., Reigner S.M., Eisner M., Weichert A., Frey N. Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease. British Journal of Clinical Pharmacology 86, 801-811, 2020.
  6. Lu D., Lu T., Gibiansky L., Li X. Li C., Agarwal P., Shemesh C.S., Shi R., Dere R.C., Hirata J., Miles D., Chanu P., Girish S., Jin J.Y.Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients with Non- Hodgkin Lymphoma. Clinical Pharmacology Therapeutics: Pharmacometry and System Pharmacology 9, 48-59, 2020.
  7. Lu T., Gibiansky L., Li X. Li C., Shi R., Agarwal P., Hirata J., Miles D., Chanu P., Girish S., Jin J.Y. Lu D. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma, 61, 2905-2914, 2020.
  8. Lu D., Lu T., Shi R., Gibiansky L., Agarwal P., Shemesh C.S., Dere R.C., Ogbu U, Hirata J., Chanu P., Girish S., Jin J.Y., Li C., Miles D. Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma. Pharmaceutical Research, https://doi.org/10.1007/s11095-020-02933-6, published online December 1, 2020.
  9. Shemesh C.S., Chanu P., Jamsen K., Wada R., Rossato G., Donaldson F., Garg A., Winter H., Ruppel J., Wang X., Bruno R., Jin J.Y.,Girish S. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Journal for ImmunoTherapy of Cancer, doi: 10.1186/s40425-019-0791-x., published online November 21, 2019.
  10. Chanu P., Gao X., Bruno R., Claret L., Harnisch L. A modeling and simulation- based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension. Journal of Pharmacokinetics and Pharmacodynamics 46, 499-509, 2019.
  11. Han K., Chanu P., Jonsson F., Winter H., Bruno R., Jin J., Stroh M. Exposure- Response and Tumor Growth Inhibition analyses of the monovalent anti-c-MET antibody onartuzumab (MetMAb) in the second- and third-line Non-Small Cell Lung Cancer. AAPS Journal 19, 527-533, 2017.
  12. Claret L., Zheng J., Mercier F., Chanu P., Chen Y., Rosbrook B., Yazdi P., Milligan P.A., Bruno R. Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline. Cancer Chemotherapy and Pharmacology, 78, 605-610, 2016.
  13. Bruno R., Lindbom L., Schaedeli Stark F., Chanu P., Gilberg F., Frey N., Claret L. Simulations to assess Phase II non-inferiority trials of different doses of capecitabine in combination with docetaxel for metastatic breast cancer. Clinical Pharmacology Therapeutics: Pharmacometry and System Pharmacology, 1, e19, doi:10.1038/psp.2012.20, published online 26 December 2012.
  14. Chanu P., Gieschke R., Charoin J.E., Pannier A., Reigner B. – Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia. Journal of Clinical Pharmacology, 50(5), 507-520, 2010.
  15. Snoeck E., Chanu P., Lavielle M., Jacqmin P., Jonsson E.N., Jorga K., Goggin T., Grippo J., Jumbe N.L., Frey N. – A comprehensive hepatitis C viral kinetic model explaining cure. Clinical Pharmacology Therapeutics, 87(6), 706-713, 2010. AAPS (American Association of Pharmaceutical Scientists) Outstanding Manuscript Award in Modeling and Simulation.
  16. Rayner C.R., Chanu P., Gieschke R., Boak L.M., Jonsson E.N. – Population pharmacokinetics of oseltamivir when coadministered with probenecid. Journal of Clinical Pharmacology, 48(8), 935-947, 2008.
More publications